Publications

2021
Hua Lin, Sharabi, Kfir , Lin, Li , Ruiz, Claudia , Zhu, Di , Cameron, Michael D, Novick, Scott J, Griffin, Patrick R, Puigserver, Pere , and Kamenecka, Theodore M. 2021. Structure-Activity Relationship And Biological Investigation Of Sr18292 (), A Suppressor Of Glucagon-Induced Glucose Production. J Med Chem. doi:10.1021/acs.jmedchem.0c01450. Abstract
Despite a myriad of available pharmacotherapies for the treatment of type 2 diabetes (T2D), challenges still exist in achieving glycemic control. Several novel glucose-lowering strategies are currently under clinical investigation, highlighting the need for more robust treatments. Previously, we have shown that suppressing peroxisome proliferator-activated receptor gamma coactivator 1-alpha activity with a small molecule (SR18292, ) can reduce glucose release from hepatocytes and ameliorate hyperglycemia in diabetic mouse models. Despite structural similarities in to known β-blockers, detailed structure-activity relationship studies described herein have led to the identification of analogues lacking β-adrenergic activity that still maintain the ability to suppress glucagon-induced glucose release from hepatocytes and ameliorate hyperglycemia in diabetic mouse models. Hence, these compounds exert their biological effects in a mechanism that does not include adrenergic signaling. These probe molecules may lead to a new therapeutic approach to treat T2D either as a single agent or in combination therapy.
2020
Marta Cruces-Sande, Arcones, Alba C, Vila-Bedmar, Rocío , Val-Blasco, Almudena , Sharabi, Kfir , Díaz-Rodríguez, Daniel , Puigserver, Pere , Mayor, Federico , and Murga, Cristina . 2020. Autophagy Mediates Hepatic Grk2 Degradation To Facilitate Glucagon-Induced Metabolic Adaptation To Fasting. Faseb J, 34, 1, Pp. 399-409. doi:10.1096/fj.201901444R. Abstract
The liver plays a key role during fasting to maintain energy homeostasis and euglycemia via metabolic processes mainly orchestrated by the insulin/glucagon ratio. We report here that fasting or calorie restriction protocols in C57BL6 mice promote a marked decrease in the hepatic protein levels of G protein-coupled receptor kinase 2 (GRK2), an important negative modulator of both G protein-coupled receptors (GPCRs) and insulin signaling. Such downregulation of GRK2 levels is liver-specific and can be rapidly reversed by refeeding. We find that autophagy, and not the proteasome, represents the main mechanism implicated in fasting-induced GRK2 degradation in the liver in vivo. Reducing GRK2 levels in murine primary hepatocytes facilitates glucagon-induced glucose production and enhances the expression of the key gluconeogenic enzyme Pck1. Conversely, preventing full downregulation of hepatic GRK2 during fasting using adenovirus-driven overexpression of this kinase in the liver leads to glycogen accumulation, decreased glycemia, and hampered glucagon-induced gluconeogenesis, thus preventing a proper and complete adaptation to nutrient deprivation. Overall, our data indicate that physiological fasting-induced downregulation of GRK2 in the liver is key for allowing complete glucagon-mediated responses and efficient metabolic adaptation to fasting in vivo.
M. Cruces-Sande, Arcones, A. C. , Vila-Bedmar, R. , Val-Blasco, A. , Sharabi, K. , Diaz-Rodriguez, D. , Puigserver, P. , Mayor, F., Jr. , and Murga, C. . 2020. Autophagy Mediates Hepatic Grk2 Degradation To Facilitate Glucagon-Induced Metabolic Adaptation To Fasting. Faseb J, 34, Pp. 399-409. Abstract
The liver plays a key role during fasting to maintain energy homeostasis and euglycemia via metabolic processes mainly orchestrated by the insulin/glucagon ratio. We report here that fasting or calorie restriction protocols in C57BL6 mice promote a marked decrease in the hepatic protein levels of G protein-coupled receptor kinase 2 (GRK2), an important negative modulator of both G protein-coupled receptors (GPCRs) and insulin signaling. Such downregulation of GRK2 levels is liver-specific and can be rapidly reversed by refeeding. We find that autophagy, and not the proteasome, represents the main mechanism implicated in fasting-induced GRK2 degradation in the liver in vivo. Reducing GRK2 levels in murine primary hepatocytes facilitates glucagon-induced glucose production and enhances the expression of the key gluconeogenic enzyme Pck1. Conversely, preventing full downregulation of hepatic GRK2 during fasting using adenovirus-driven overexpression of this kinase in the liver leads to glycogen accumulation, decreased glycemia, and hampered glucagon-induced gluconeogenesis, thus preventing a proper and complete adaptation to nutrient deprivation. Overall, our data indicate that physiological fasting-induced downregulation of GRK2 in the liver is key for allowing complete glucagon-mediated responses and efficient metabolic adaptation to fasting in vivo.
C. Luo, Liang, J. , Sharabi, K. , Hatting, M. , Perry, E. A. , Tavares, C. D. J. , Goyal, L. , Srivastava, A. , Bilodeau, M. , Zhu, A. X. , Sicinski, P. , and Puigserver, P. . 2020. Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive To Cyclin D1 Deficiency. Cancer Res. Abstract
Type 2 diabetes, which is mainly linked to obesity, is associated with increased incidence of liver cancer. We have previously found that in various models of obesity/diabetes, hyperinsulinemia maintains heightened hepatic expression of cyclin D1, suggesting a plausible mechanism linking diabetes and liver cancer progression. Here we show that cyclin D1 is greatly elevated in human livers with diabetes and is among the most significantly upregulated genes in obese/diabetic liver tumors. Liver-specific cyclin D1 deficiency protected obese/diabetic mice against hepatic tumorigenesis, whereas lean/nondiabetic mice developed tumors irrespective of cyclin D1 status. Cyclin D1 dependency positively correlated with liver cancer sensitivity to palbociclib, an FDA-approved CDK4 inhibitor, which was effective in treating orthotopic liver tumors under obese/diabetic conditions. The antidiabetic drug metformin suppressed insulin-induced hepatic cyclin D1 expression and protected against obese/diabetic hepatocarcinogenesis. These results indicate that the cyclin D1-CDK4 complex represents a potential selective therapeutic vulnerability for liver tumors in obese/diabetic patients. SIGNIFICANCE: Obesity/diabetes-associated liver tumors are specifically vulnerable to cyclin D1 deficiency and CDK4 inhibition, suggesting that the obese/diabetic environment confers cancer-selective dependencies that can be therapeutically exploited.
Chi Luo, Liang, Jiaxin , Sharabi, Kfir , Hatting, Maximilian , Perry, Elizabeth A, Tavares, Clint DJ, Goyal, Lipika , Srivastava, Amitabh , Bilodeau, Marc , Zhu, Andrew X, Sicinski, Piotr , and Puigserver, Pere . 2020. Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive To Cyclin D1 Deficiency. Cancer Res, 80, 16, Pp. 3215-3221. doi:10.1158/0008-5472.CAN-20-0106. Abstract
Type 2 diabetes, which is mainly linked to obesity, is associated with increased incidence of liver cancer. We have previously found that in various models of obesity/diabetes, hyperinsulinemia maintains heightened hepatic expression of cyclin D1, suggesting a plausible mechanism linking diabetes and liver cancer progression. Here we show that cyclin D1 is greatly elevated in human livers with diabetes and is among the most significantly upregulated genes in obese/diabetic liver tumors. Liver-specific cyclin D1 deficiency protected obese/diabetic mice against hepatic tumorigenesis, whereas lean/nondiabetic mice developed tumors irrespective of cyclin D1 status. Cyclin D1 dependency positively correlated with liver cancer sensitivity to palbociclib, an FDA-approved CDK4 inhibitor, which was effective in treating orthotopic liver tumors under obese/diabetic conditions. The antidiabetic drug metformin suppressed insulin-induced hepatic cyclin D1 expression and protected against obese/diabetic hepatocarcinogenesis. These results indicate that the cyclin D1-CDK4 complex represents a potential selective therapeutic vulnerability for liver tumors in obese/diabetic patients. SIGNIFICANCE: Obesity/diabetes-associated liver tumors are specifically vulnerable to cyclin D1 deficiency and CDK4 inhibition, suggesting that the obese/diabetic environment confers cancer-selective dependencies that can be therapeutically exploited.
C. D. J. Tavares, Aigner, S. , Sharabi, K. , Sathe, S. , Mutlu, B. , Yeo, G. W. , and Puigserver, P. . 2020. Transcriptome-Wide Analysis Of Pgc-1Alpha-Binding Rnas Identifies Genes Linked To Glucagon Metabolic Action. Proc Natl Acad Sci U S A. Abstract
The peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) is a transcriptional coactivator that controls expression of metabolic/energetic genes, programming cellular responses to nutrient and environmental adaptations such as fasting, cold, or exercise. Unlike other coactivators, PGC-1alpha contains protein domains involved in RNA regulation such as serine/arginine (SR) and RNA recognition motifs (RRMs). However, the RNA targets of PGC-1alpha and how they pertain to metabolism are unknown. To address this, we performed enhanced ultraviolet (UV) cross-linking and immunoprecipitation followed by sequencing (eCLIP-seq) in primary hepatocytes induced with glucagon. A large fraction of RNAs bound to PGC-1alpha were intronic sequences of genes involved in transcriptional, signaling, or metabolic function linked to glucagon and fasting responses, but were not the canonical direct transcriptional PGC-1alpha targets such as OXPHOS or gluconeogenic genes. Among the top-scoring RNA sequences bound to PGC-1alpha were Foxo1, Camk1delta, Per1, Klf15, Pln4, Cluh, Trpc5, Gfra1, and Slc25a25 PGC-1alpha depletion decreased a fraction of these glucagon-induced messenger RNA (mRNA) transcript levels. Importantly, knockdown of several of these genes affected glucagon-dependent glucose production, a PGC-1alpha-regulated metabolic pathway. These studies show that PGC-1alpha binds to intronic RNA sequences, some of them controlling transcript levels associated with glucagon action.
Clint DJ Tavares, Aigner, Stefan , Sharabi, Kfir , Sathe, Shashank , Mutlu, Beste , Yeo, Gene W, and Puigserver, Pere . 2020. Transcriptome-Wide Analysis Of Pgc-1Α-Binding Rnas Identifies Genes Linked To Glucagon Metabolic Action. Proc Natl Acad Sci U S A, 117, 36, Pp. 22204-22213. doi:10.1073/pnas.2000643117. Abstract
The peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a transcriptional coactivator that controls expression of metabolic/energetic genes, programming cellular responses to nutrient and environmental adaptations such as fasting, cold, or exercise. Unlike other coactivators, PGC-1α contains protein domains involved in RNA regulation such as serine/arginine (SR) and RNA recognition motifs (RRMs). However, the RNA targets of PGC-1α and how they pertain to metabolism are unknown. To address this, we performed enhanced ultraviolet (UV) cross-linking and immunoprecipitation followed by sequencing (eCLIP-seq) in primary hepatocytes induced with glucagon. A large fraction of RNAs bound to PGC-1α were intronic sequences of genes involved in transcriptional, signaling, or metabolic function linked to glucagon and fasting responses, but were not the canonical direct transcriptional PGC-1α targets such as OXPHOS or gluconeogenic genes. Among the top-scoring RNA sequences bound to PGC-1α were , δ, , , , , , , and PGC-1α depletion decreased a fraction of these glucagon-induced messenger RNA (mRNA) transcript levels. Importantly, knockdown of several of these genes affected glucagon-dependent glucose production, a PGC-1α-regulated metabolic pathway. These studies show that PGC-1α binds to intronic RNA sequences, some of them controlling transcript levels associated with glucagon action.
2019
Masahiko Shigemura, Lecuona, Emilia , Angulo, Martín , Dada, Laura A, Edwards, Melanie B, Welch, Lynn C, Casalino-Matsuda, Marina S, Sporn, Peter HS, Vadász, István , Helenius, Iiro Taneli , Nader, Gustavo A, Gruenbaum, Yosef , Sharabi, Kfir , Cummins, Eoin , Taylor, Cormac , Bharat, Ankit , Gottardi, Cara J, Beitel, Greg J, Kaminski, Naftali , Budinger, Scott GR, Berdnikovs, Sergejs , and Sznajder, Jacob I. 2019. Elevated Co Regulates The Wnt Signaling Pathway In Mammals, Drosophila Melanogaster And Caenorhabditis Elegans. Sci Rep, 9, 1, Pp. 18251. doi:10.1038/s41598-019-54683-0. Abstract
Carbon dioxide (CO) is sensed by cells and can trigger signals to modify gene expression in different tissues leading to changes in organismal functions. Despite accumulating evidence that several pathways in various organisms are responsive to CO elevation (hypercapnia), it has yet to be elucidated how hypercapnia activates genes and signaling pathways, or whether they interact, are integrated, or are conserved across species. Here, we performed a large-scale transcriptomic study to explore the interaction/integration/conservation of hypercapnia-induced genomic responses in mammals (mice and humans) as well as invertebrates (Caenorhabditis elegans and Drosophila melanogaster). We found that hypercapnia activated genes that regulate Wnt signaling in mouse lungs and skeletal muscles in vivo and in several cell lines of different tissue origin. Hypercapnia-responsive Wnt pathway homologues were similarly observed in secondary analysis of available transcriptomic datasets of hypercapnia in a human bronchial cell line, flies and nematodes. Our data suggest the evolutionarily conserved role of high CO in regulating Wnt pathway genes.
M. Shigemura, Lecuona, E. , Angulo, M. , Dada, L. A. , Edwards, M. B. , Welch, L. C. , Casalino-Matsuda, S. M. , Sporn, P. H. S. , Vadasz, I. , Helenius, I. T. , Nader, G.A. , Gruenbaum, Y. , Sharabi, K. , Cummins, E. , Taylor, C. , Bharat, A. , Gottardi, C. J. , Beitel, G. J. , Kaminski, N. , Budinger, G. R. S. , Berdnikovs, S. , and Sznajder, J. I. . 2019. Elevated Co2 Regulates The Wnt Signaling Pathway In Mammals, Drosophila Melanogaster And Caenorhabditis Elegans. Sci Rep, 9, Pp. 18251. Abstract
Carbon dioxide (CO2) is sensed by cells and can trigger signals to modify gene expression in different tissues leading to changes in organismal functions. Despite accumulating evidence that several pathways in various organisms are responsive to CO2 elevation (hypercapnia), it has yet to be elucidated how hypercapnia activates genes and signaling pathways, or whether they interact, are integrated, or are conserved across species. Here, we performed a large-scale transcriptomic study to explore the interaction/integration/conservation of hypercapnia-induced genomic responses in mammals (mice and humans) as well as invertebrates (Caenorhabditis elegans and Drosophila melanogaster). We found that hypercapnia activated genes that regulate Wnt signaling in mouse lungs and skeletal muscles in vivo and in several cell lines of different tissue origin. Hypercapnia-responsive Wnt pathway homologues were similarly observed in secondary analysis of available transcriptomic datasets of hypercapnia in a human bronchial cell line, flies and nematodes. Our data suggest the evolutionarily conserved role of high CO2 in regulating Wnt pathway genes.
Kfir Sharabi, Tavares, Clint DJ, and Puigserver, Pere . 2019. Regulation Of Hepatic Metabolism, Recent Advances, And Future Perspectives. Curr Diab Rep, 19, 10, Pp. 98. doi:10.1007/s11892-019-1224-4. Abstract
PURPOSE OF REVIEW: The purpose of this review is to provide a brief summary of recent advances in our understanding of liver metabolism. The critical role of the liver in controlling whole-body energy homeostasis makes such understanding crucial to efficiently design new treatments for metabolic syndrome diseases, including type 2 diabetes (T2D). RECENT FINDINGS: Significant advances have been made regarding our understanding of the direct and indirect effects of insulin on hepatic metabolism and the communication between the liver and other tissues. Moreover, the catabolic functions of glucagon, as well as the importance of hepatic redox status for the regulation of glucose production, are emerging as potential targets to reduce hyperglycemia. A resolution to the long-standing question "insulin suppression of hepatic glucose production, direct or indirect effect?" is starting to emerge. New advances in our understanding of important fasting-induced hepatic metabolic fluxes may help design better therapies for T2D.
K. Sharabi, Tavares, C. D. J. , and Puigserver, P. . 2019. Regulation Of Hepatic Metabolism, Recent Advances, And Future Perspectives. Curr Diab Rep, 19, Pp. 98. Abstract
PURPOSE OF REVIEW: The purpose of this review is to provide a brief summary of recent advances in our understanding of liver metabolism. The critical role of the liver in controlling whole-body energy homeostasis makes such understanding crucial to efficiently design new treatments for metabolic syndrome diseases, including type 2 diabetes (T2D). RECENT FINDINGS: Significant advances have been made regarding our understanding of the direct and indirect effects of insulin on hepatic metabolism and the communication between the liver and other tissues. Moreover, the catabolic functions of glucagon, as well as the importance of hepatic redox status for the regulation of glucose production, are emerging as potential targets to reduce hyperglycemia. A resolution to the long-standing question "insulin suppression of hepatic glucose production, direct or indirect effect?" is starting to emerge. New advances in our understanding of important fasting-induced hepatic metabolic fluxes may help design better therapies for T2D.
2018
M. Hatting, Tavares, C. D. J. , Sharabi, K. , Rines, A. K. , and Puigserver, P. . 2018. Insulin Regulation Of Gluconeogenesis. Ann N Y Acad Sci, 1411, Pp. 21-35. Abstract
The coordinated regulation between cellular glucose uptake and endogenous glucose production is indispensable for the maintenance of constant blood glucose concentrations. The liver contributes significantly to this process by altering the levels of hepatic glucose release, through controlling the processes of de novo glucose production (gluconeogenesis) and glycogen breakdown (glycogenolysis). Various nutritional and hormonal stimuli signal to alter hepatic gluconeogenic flux, and suppression of this metabolic pathway during the postprandial state can, to a significant extent, be attributed to insulin. Here, we review some of the molecular mechanisms through which insulin modulates hepatic gluconeogenesis, thus controlling glucose production by the liver to ultimately maintain normoglycemia. Various signaling pathways governed by insulin converge at the level of transcriptional regulation of the key hepatic gluconeogenic genes PCK1 and G6PC, highlighting this as one of the focal mechanisms through which gluconeogenesis is modulated. In individuals with compromised insulin signaling, such as insulin resistance in type 2 diabetes, insulin fails to suppress hepatic gluconeogenesis, even in the fed state; hence, an insight into these insulin-moderated pathways is critical for therapeutic purposes.
Maximilian Hatting, Tavares, Clint DJ, Sharabi, Kfir , Rines, Amy K, and Puigserver, Pere . 2018. Insulin Regulation Of Gluconeogenesis. Ann N Y Acad Sci, 1411, 1, Pp. 21-35. doi:10.1111/nyas.13435. Abstract
The coordinated regulation between cellular glucose uptake and endogenous glucose production is indispensable for the maintenance of constant blood glucose concentrations. The liver contributes significantly to this process by altering the levels of hepatic glucose release, through controlling the processes of de novo glucose production (gluconeogenesis) and glycogen breakdown (glycogenolysis). Various nutritional and hormonal stimuli signal to alter hepatic gluconeogenic flux, and suppression of this metabolic pathway during the postprandial state can, to a significant extent, be attributed to insulin. Here, we review some of the molecular mechanisms through which insulin modulates hepatic gluconeogenesis, thus controlling glucose production by the liver to ultimately maintain normoglycemia. Various signaling pathways governed by insulin converge at the level of transcriptional regulation of the key hepatic gluconeogenic genes PCK1 and G6PC, highlighting this as one of the focal mechanisms through which gluconeogenesis is modulated. In individuals with compromised insulin signaling, such as insulin resistance in type 2 diabetes, insulin fails to suppress hepatic gluconeogenesis, even in the fed state; hence, an insight into these insulin-moderated pathways is critical for therapeutic purposes.
2017
M. Hatting, Rines, A. K. , Luo, C. , Tabata, M. , Sharabi, K. , Hall, J. A. , Verdeguer, F. , Trautwein, C. , and Puigserver, P. . 2017. Adipose Tissue Clk2 Promotes Energy Expenditure During High-Fat Diet Intermittent Fasting. Cell Metab, 25, Pp. 428-437. Abstract
A promising approach to treating obesity is to increase diet-induced thermogenesis in brown adipose tissue (BAT), but the regulation of this process remains unclear. Here we find that CDC-like kinase 2 (CLK2) is expressed in BAT and upregulated upon refeeding. Mice lacking CLK2 in adipose tissue exhibit exacerbated obesity and decreased energy expenditure during high-fat diet intermittent fasting. Additionally, tissue oxygen consumption and protein levels of UCP1 are reduced in CLK2-deficient BAT. Phosphorylation of CREB, a transcriptional activator of UCP1, is markedly decreased in BAT cells lacking CLK2 due to enhanced CREB dephosphorylation. Mechanistically, CREB dephosphorylation is rescued by the inhibition of PP2A, a phosphatase that targets CREB. Our results suggest that CLK2 is a regulatory component of diet-induced thermogenesis in BAT through increased CREB-dependent expression of UCP1.
Maximilian Hatting, Rines, Amy K, Luo, Chi , Tabata, Mitsuhisa , Sharabi, Kfir , Hall, Jessica A, Verdeguer, Francisco , Trautwein, Christian , and Puigserver, Pere . 2017. Adipose Tissue Clk2 Promotes Energy Expenditure During High-Fat Diet Intermittent Fasting. Cell Metab, 25, 2, Pp. 428-437. doi:10.1016/j.cmet.2016.12.007. Abstract
A promising approach to treating obesity is to increase diet-induced thermogenesis in brown adipose tissue (BAT), but the regulation of this process remains unclear. Here we find that CDC-like kinase 2 (CLK2) is expressed in BAT and upregulated upon refeeding. Mice lacking CLK2 in adipose tissue exhibit exacerbated obesity and decreased energy expenditure during high-fat diet intermittent fasting. Additionally, tissue oxygen consumption and protein levels of UCP1 are reduced in CLK2-deficient BAT. Phosphorylation of CREB, a transcriptional activator of UCP1, is markedly decreased in BAT cells lacking CLK2 due to enhanced CREB dephosphorylation. Mechanistically, CREB dephosphorylation is rescued by the inhibition of PP2A, a phosphatase that targets CREB. Our results suggest that CLK2 is a regulatory component of diet-induced thermogenesis in BAT through increased CREB-dependent expression of UCP1.
K. Sharabi, Lin, H. , Tavares, C. D. J. , Dominy, J. E. , Camporez, J. P. , Perry, R. J. , Schilling, R. , Rines, A. K. , Lee, J. , Hickey, M. , Bennion, M. , Palmer, M. , Nag, P. P. , Bittker, J. A. , Perez, J. , Jedrychowski, M. P. , Ozcan, U. , Gygi, S. P. , Kamenecka, T. M. , Shulman, G. I. , Schreiber, S. L. , Griffin, P. R. , and Puigserver, P. . 2017. Selective Chemical Inhibition Of Pgc-1Alpha Gluconeogenic Activity Ameliorates Type 2 Diabetes. Cell, 169, Pp. 148-160 e15. Abstract
Type 2 diabetes (T2D) is a worldwide epidemic with a medical need for additional targeted therapies. Suppression of hepatic glucose production (HGP) effectively ameliorates diabetes and can be exploited for its treatment. We hypothesized that targeting PGC-1alpha acetylation in the liver, a chemical modification known to inhibit hepatic gluconeogenesis, could be potentially used for treatment of T2D. Thus, we designed a high-throughput chemical screen platform to quantify PGC-1alpha acetylation in cells and identified small molecules that increase PGC-1alpha acetylation, suppress gluconeogenic gene expression, and reduce glucose production in hepatocytes. On the basis of potency and bioavailability, we selected a small molecule, SR-18292, that reduces blood glucose, strongly increases hepatic insulin sensitivity, and improves glucose homeostasis in dietary and genetic mouse models of T2D. These studies have important implications for understanding the regulatory mechanisms of glucose metabolism and treatment of T2D.
Kfir Sharabi, Lin, Hua , Tavares, Clint DJ, Dominy, John E, Camporez, Joao Paulo , Perry, Rachel J, Schilling, Roger , Rines, Amy K, Lee, Jaemin , Hickey, Marc , Bennion, Melissa , Palmer, Michelle , Nag, Partha P, Bittker, Joshua A, Perez, José , Jedrychowski, Mark P, Ozcan, Umut , Gygi, Steve P, Kamenecka, Theodore M, Shulman, Gerald I, Schreiber, Stuart L, Griffin, Patrick R, and Puigserver, Pere . 2017. Selective Chemical Inhibition Of Pgc-1Α Gluconeogenic Activity Ameliorates Type 2 Diabetes. Cell, 169, 1, Pp. 148-160.e15. doi:10.1016/j.cell.2017.03.001. Abstract
Type 2 diabetes (T2D) is a worldwide epidemic with a medical need for additional targeted therapies. Suppression of hepatic glucose production (HGP) effectively ameliorates diabetes and can be exploited for its treatment. We hypothesized that targeting PGC-1α acetylation in the liver, a chemical modification known to inhibit hepatic gluconeogenesis, could be potentially used for treatment of T2D. Thus, we designed a high-throughput chemical screen platform to quantify PGC-1α acetylation in cells and identified small molecules that increase PGC-1α acetylation, suppress gluconeogenic gene expression, and reduce glucose production in hepatocytes. On the basis of potency and bioavailability, we selected a small molecule, SR-18292, that reduces blood glucose, strongly increases hepatic insulin sensitivity, and improves glucose homeostasis in dietary and genetic mouse models of T2D. These studies have important implications for understanding the regulatory mechanisms of glucose metabolism and treatment of T2D.
2016
Clint DJ Tavares, Sharabi, Kfir , Dominy, John E, Lee, Yoonjin , Isasa, Marta , Orozco, Jose M, Jedrychowski, Mark P, Kamenecka, Theodore M, Griffin, Patrick R, Gygi, Steven P, and Puigserver, Pere . 2016. The Methionine Transamination Pathway Controls Hepatic Glucose Metabolism Through Regulation Of The Gcn5 Acetyltransferase And The Pgc-1Α Transcriptional Coactivator. J Biol Chem, 291, 20, Pp. 10635-45. doi:10.1074/jbc.M115.706200. Abstract
Methionine is an essential sulfur amino acid that is engaged in key cellular functions such as protein synthesis and is a precursor for critical metabolites involved in maintaining cellular homeostasis. In mammals, in response to nutrient conditions, the liver plays a significant role in regulating methionine concentrations by altering its flux through the transmethylation, transsulfuration, and transamination metabolic pathways. A comprehensive understanding of how hepatic methionine metabolism intersects with other regulatory nutrient signaling and transcriptional events is, however, lacking. Here, we show that methionine and derived-sulfur metabolites in the transamination pathway activate the GCN5 acetyltransferase promoting acetylation of the transcriptional coactivator PGC-1α to control hepatic gluconeogenesis. Methionine was the only essential amino acid that rapidly induced PGC-1α acetylation through activating the GCN5 acetyltransferase. Experiments employing metabolic pathway intermediates revealed that methionine transamination, and not the transmethylation or transsulfuration pathways, contributed to methionine-induced PGC-1α acetylation. Moreover, aminooxyacetic acid, a transaminase inhibitor, was able to potently suppress PGC-1α acetylation stimulated by methionine, which was accompanied by predicted alterations in PGC-1α-mediated gluconeogenic gene expression and glucose production in primary murine hepatocytes. Methionine administration in mice likewise induced hepatic PGC-1α acetylation, suppressed the gluconeogenic gene program, and lowered glycemia, indicating that a similar phenomenon occurs in vivo These results highlight a communication between methionine metabolism and PGC-1α-mediated hepatic gluconeogenesis, suggesting that influencing methionine metabolic flux has the potential to be therapeutically exploited for diabetes treatment.
C. D. Tavares, Sharabi, K. , Dominy, J. E. , Lee, Y. , Isasa, M. , Orozco, J. M. , Jedrychowski, M. P. , Kamenecka, T. M. , Griffin, P. R. , Gygi, S. P. , and Puigserver, P. . 2016. The Methionine Transamination Pathway Controls Hepatic Glucose Metabolism Through Regulation Of The Gcn5 Acetyltransferase And The Pgc-1Alpha Transcriptional Coactivator. J Biol Chem, 291, Pp. 10635-45. Abstract
Methionine is an essential sulfur amino acid that is engaged in key cellular functions such as protein synthesis and is a precursor for critical metabolites involved in maintaining cellular homeostasis. In mammals, in response to nutrient conditions, the liver plays a significant role in regulating methionine concentrations by altering its flux through the transmethylation, transsulfuration, and transamination metabolic pathways. A comprehensive understanding of how hepatic methionine metabolism intersects with other regulatory nutrient signaling and transcriptional events is, however, lacking. Here, we show that methionine and derived-sulfur metabolites in the transamination pathway activate the GCN5 acetyltransferase promoting acetylation of the transcriptional coactivator PGC-1alpha to control hepatic gluconeogenesis. Methionine was the only essential amino acid that rapidly induced PGC-1alpha acetylation through activating the GCN5 acetyltransferase. Experiments employing metabolic pathway intermediates revealed that methionine transamination, and not the transmethylation or transsulfuration pathways, contributed to methionine-induced PGC-1alpha acetylation. Moreover, aminooxyacetic acid, a transaminase inhibitor, was able to potently suppress PGC-1alpha acetylation stimulated by methionine, which was accompanied by predicted alterations in PGC-1alpha-mediated gluconeogenic gene expression and glucose production in primary murine hepatocytes. Methionine administration in mice likewise induced hepatic PGC-1alpha acetylation, suppressed the gluconeogenic gene program, and lowered glycemia, indicating that a similar phenomenon occurs in vivo These results highlight a communication between methionine metabolism and PGC-1alpha-mediated hepatic gluconeogenesis, suggesting that influencing methionine metabolic flux has the potential to be therapeutically exploited for diabetes treatment.
Amy K Rines, Sharabi, Kfir , Tavares, Clint DJ, and Puigserver, Pere . 2016. Targeting Hepatic Glucose Metabolism In The Treatment Of Type 2 Diabetes. Nat Rev Drug Discov, 15, 11, Pp. 786-804. doi:10.1038/nrd.2016.151. Abstract
Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia. Although current diabetes treatments have exhibited some success in lowering blood glucose levels, their effect is not always sustained and their use may be associated with undesirable side effects, such as hypoglycaemia. Novel antidiabetic drugs, which may be used in combination with existing therapies, are therefore needed. The potential of specifically targeting the liver to normalize blood glucose levels has not been fully exploited. Here, we review the molecular mechanisms controlling hepatic gluconeogenesis and glycogen storage, and assess the prospect of therapeutically targeting associated pathways to treat type 2 diabetes.

Pages